- Home
- SPRO vs PROP Comparison
SPRO vs PROP Comparison
Compare SPRO & PROP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- PROP
- Stock Information
- Founded
- SPRO 2013
- PROP 2001
- Country
- SPRO United States
- PROP United States
- Employees
- SPRO N/A
- PROP N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- PROP Investment Bankers/Brokers/Service
- Sector
- SPRO Health Care
- PROP Finance
- Exchange
- SPRO Nasdaq
- PROP Nasdaq
- Market Cap
- SPRO 162.1M
- PROP 168.7M
- IPO Year
- SPRO 2017
- PROP N/A
- Fundamental
- Price
- SPRO $2.20
- PROP $3.59
- Analyst Decision
- SPRO Buy
- PROP Strong Buy
- Analyst Count
- SPRO 4
- PROP 5
- Target Price
- SPRO $5.00
- PROP $8.50
- AVG Volume (30 Days)
- SPRO 789.2K
- PROP 1.5M
- Earning Date
- SPRO 08-04-2025
- PROP 08-15-2025
- Dividend Yield
- SPRO N/A
- PROP N/A
- EPS Growth
- SPRO N/A
- PROP N/A
- EPS
- SPRO N/A
- PROP N/A
- Revenue
- SPRO $44,584,000.00
- PROP $21,529,000.00
- Revenue This Year
- SPRO N/A
- PROP $5,710.68
- Revenue Next Year
- SPRO N/A
- PROP $28.49
- P/E Ratio
- SPRO N/A
- PROP N/A
- Revenue Growth
- SPRO N/A
- PROP N/A
- 52 Week Low
- SPRO $0.51
- PROP $2.74
- 52 Week High
- SPRO $3.22
- PROP $12.30
- Technical
- Relative Strength Index (RSI)
- SPRO 33.44
- PROP 45.57
- Support Level
- SPRO $2.30
- PROP $3.67
- Resistance Level
- SPRO $2.45
- PROP $4.00
- Average True Range (ATR)
- SPRO 0.12
- PROP 0.31
- MACD
- SPRO -0.07
- PROP 0.01
- Stochastic Oscillator
- SPRO 2.80
- PROP 21.32
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About PROP Prairie Operating Co.
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.